Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Biofrontera AG    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:30am EDT

Leverkusen, Germany, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2019 on August 27, 2019.

Conference calls for shareholders and interested investors will be held on August 27, 2019 at the following times:

In German, at 10:00 am CET (4:00 am ET)
Dial-in number Germany: +49 69201744220
Conference code: 74039909#

In English, at 2:00 pm CET (8:00 am ET)
Dial-in number USA: +1 8774230830
Dial-in number UK: +44 2030092470
Conference code: 89026773#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

 -END-

For enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer
 

+49 (0) 214 87 63 2 0

ir@biofrontera.com
IR UK: Seton Services

Toni Vallen
 

+44 (0) 207 229 0805
IR and PR US: The Ruth Group

IR: Tram Bui

PR: Kirsten Thomas
 

+1 646-536-7035

+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi®, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOFRONTERA AG
08/14BIOFRONTERA AG : Biofrontera Announces Conference Call on August 27, 2019 to Dis..
EQ
08/14Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year..
GL
08/08BIOFRONTERA AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
08/05BIOFRONTERA AG : Biofrontera provides update on Cutanea integration
EQ
07/31BIOFRONTERA AG : Release according to Article 41 of the WpHG [the German Securit..
EQ
07/29BIOFRONTERA AG : Notification and public disclosure of transactions by persons
EQ
07/29BIOFRONTERA AG : Release according to Article 40, Section 1 of the WpHG [the Ger..
EQ
07/24BIOFRONTERA AG : Results of the voluntary partial tender offers
EQ
07/24Results of the voluntary partial tender offers
GL
07/11BIOFRONTERA AG : Annual General Meeting of Biofrontera AG: Biofrontera Managemen..
EQ
More news
Financials (EUR)
Sales 2019 36,0 M
EBIT 2019 -9,10 M
Net income 2019 -10,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -28,7x
P/E ratio 2020 82,4x
Capi. / Sales2019 8,31x
Capi. / Sales2020 5,21x
Capitalization 299 M
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 8,97  €
Last Close Price 6,59  €
Spread / Highest target 36,6%
Spread / Average Target 36,1%
Spread / Lowest Target 35,1%
EPS Revisions
Managers
NameTitle
Hermann Lübbert Chairman-Management Board & CEO
Ulrich Granzer Chairman-Supervisory Board
Thomas Schaffer Chief Financial Officer
Jürgen Christian Baumann Vice Chairman-Supervisory Board
Hansjörg Plaggemars Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIOFRONTERA AG33.73%333
CSL LIMITED29.00%73 105
BIOGEN INC.-24.95%41 657
ALEXION PHARMACEUTICALS18.46%25 860
GRIFOLS25.94%19 335
SAMSUNG BIOLOGICS CO LTD--.--%15 467